Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

ABSTRACT: Advanced Epithelial Ovarian Cancer (EOC) patients frequently relapse by 24 months and develop resistant disease. Research on EOC therapies relies on cancer cell lines established decades ago making Patient Derived Xenografts (PDX) attractive models, because they are faithful representations of the original tumor. We established 35 ovarian cancer PDXs resulting from the original graft of 77 EOC samples onto immuno-compromised mice. PDXs covered the diversity of EOC histotypes and graft take was correlated with early patient death. Fourteen PDXs were characterized at the genetic and histological levels. PDXs reproduced phenotypic features of the ovarian tumors of origin and conserved the principal characteristics of the original copy number change (CNC) profiles over several passages. Howeve

SUBMITTER: Colombo PE 

PROVIDER: S-EPMC4695063 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature